RespireRx Pharmaceuticals Inc (fka RSPI)

[moosedogger]

you said: "To be honest, I've never really understood the nature of the explanation, "we don't want to give away trade secrets to our competition." How an anomaly in a patent-protected compound of Cortex is giving away the kitchen sink doesn't seem like a full explanation."

We know Lilly has had ampakine problems and has been stopped by the FDA. For all we know that's why COR was stopped.

Since Lilly isn't helping COR (seems the opposite), why should COR help Lilly (potentially) by being completely open about what the FDA concerns have been?

I think Stoll has handled it completely right so far.